Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. - Wikidata - wikimedia - TriplyDB

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

http://www.wikidata.org/entity/Q33385313

about

Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Treatment of hepatocellular carcinoma: Steps forward but still a long way to go Systemic therapy of hepatocellular carcinoma: current status and future perspectives Current systemic treatment of hepatocellular carcinoma: A review of the literature Molecular classification and novel targets in hepatocellular carcinoma: recent advancements Challenges of incorporating gene expression data to predict HCC prognosis in the age of systems biology Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.Molecular genetics of hepatocellular neoplasia.Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.A multidisciplinary approach to the management of hepatocellular carcinoma.Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).Liver cancer: Targeted future options Targeting metastatic upper gastrointestinal adenocarcinomas Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.Major challenges limiting liver transplantation in the United States.Targeted therapy in hepatocellular carcinoma Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.HCC and angiogenesis: possible targets and future directions Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.Dalbinol, a rotenoid from Amorpha fruticosa L., exerts anti-proliferative activity by facilitating β-catenin degradation in hepatocellular carcinoma cells.Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence Sorafenib: where do we go from here?Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study Targeted therapies for hepatocellular carcinoma.Molecular approaches to treatment of hepatocellular carcinoma.Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy

P2860

Q26766689-4AA25036-9491-4D80-8CF1-7165573E2908 Q26865456-F19219FB-BE45-4289-B74D-719C03087B08 Q26865844-33E42103-7B16-4231-8F37-B599C01681DC Q27026036-A9D01E08-8C99-4853-BC09-E354517FFC38 Q28383646-911272B6-8AF0-460E-82DB-66EB0DAF3DC1 Q30558695-99EB397F-71F1-4D5E-8DC8-2DA44557FBBF Q33396181-03BDBE18-2194-4713-90BE-1DD531A0A4A7 Q33660974-03EC72A9-2D48-4E93-9B93-A15F73110918 Q33680701-FCDF1D02-AC13-498A-9220-54AC0A1BAE45 Q33742856-D9C94693-EF8C-487C-9D22-191BC85F8332 Q33820376-1F570509-9AED-461B-90E0-079EF033E9D8 Q33916361-75C46793-CF7C-48A9-890A-39EDE51DA135 Q33944599-4BB7302B-76E4-47FB-9843-4ED5979E4744 Q34131801-7AAC0367-862D-478B-9467-159AC12BCBA2 Q34250125-2D10C6B9-BF50-46E1-8458-CCA0D2E05B48 Q34504649-4CA4160B-EFB2-4C54-899B-BBED08C459AA Q34548464-95FCA45B-8A45-484C-B528-DCDE1DEAD56C Q34617414-C5FE496B-337F-4E0D-9AF8-F3B2B3EA5E30 Q34695180-9335CEC8-14D5-4527-A666-45FBCBE27A6F Q35000785-9F1F98D6-1516-4BF3-A4B2-C483AA03797A Q35184195-D8C79FF0-F277-4AB1-A7B0-09279BA5A0CA Q35194675-FE5D3F6D-5C9A-4809-A500-D6A8FD242E90 Q35207561-A31F8A92-8A46-462E-82B1-8CAD8281A397 Q35230282-02E93C26-0248-4B2E-8FC0-10E11A4117F1 Q35501246-0355ECDA-C761-4A1A-A787-C49075A036A8 Q35541482-8EBB152D-AF97-4D7F-8951-8DA50A35135D Q35640101-5FA4BC3F-4464-4F3E-B3B2-E97FE97E00C8 Q35689747-BECE3910-7379-493E-B8E1-FAA30E2A60FF Q35698574-E2C44723-66E7-40E1-9292-205276BDA001 Q35739362-8C936F63-9550-4DBC-8ADC-D29D52B46083 Q35913461-F58A2A66-2D16-44A0-A221-6A39D305D507 Q36182824-F14E0082-3DAF-47AC-B690-A2814CA687FA Q36382856-544EEEA7-8F0D-4901-9774-58D05B8795EA Q36644408-67970395-B373-4AE7-86E6-030D573FA318 Q36675015-DB5787FF-6372-4D00-89EE-37EF0CE8FC6A Q36708741-67F9A588-4006-44FE-9325-9B88AF74F0F6 Q36720049-21365E17-9F12-403C-BAC9-D28033700AD8 Q36928888-8B804E8E-0998-4694-AABB-16C1EBED493C Q36955912-C80741B9-B7C4-4151-A501-4275F8A4AC22 Q37042355-065F0920-007A-4B11-A704-BFCC29587FF5

P2860

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

http://www.wikidata.org/entity/Q33385313

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety and efficacy of sunitin ...... , multicentre, phase II study.

@ast

Safety and efficacy of sunitin ...... , multicentre, phase II study.

@en

type

label

Safety and efficacy of sunitin ...... , multicentre, phase II study.

@ast

Safety and efficacy of sunitin ...... , multicentre, phase II study.

@en

prefLabel

Safety and efficacy of sunitin ...... , multicentre, phase II study.

@ast

Safety and efficacy of sunitin ...... , multicentre, phase II study.

@en

P1433

Q33385313-919FA39D-4575-4CC8-BDCB-768918BCF69F

P1476

Q33385313-C67B3B7C-418A-488A-A753-420925D333EB

P2093

Q33385313-0F7ABF3E-E031-4A85-AD5A-7E149CAFD9EF

Q33385313-135AE0A6-892C-447F-AB67-79CB139CAC12

Q33385313-4E8734A6-6E62-4A47-BBC9-1363ECE858E4

Q33385313-99C701AA-9BC5-44D8-80AC-DFEFF0E899FE

Q33385313-A43CA395-F6C0-4F89-8928-8F7492C969C9

Q33385313-AD0207FC-F148-4E4B-BD72-FE2F7BA82903

Q33385313-BC3520CA-5685-4875-B0F7-77B9BB8FDE45

Q33385313-C76417BD-25E4-4F7A-8516-971948CDF8C1

Q33385313-DB4F53AD-30CA-484A-A4D0-02F294BC0C87

Q33385313-EA5FF6D5-761B-45D0-8047-E088D25F08E1

P304

Q33385313-0BCF17C0-66F4-4F6E-8CC0-C21099F806D3

P31

Q33385313-341025CF-CE26-4F8C-9E72-EB2729D8DECC

P356

Q33385313-46A2146E-229B-44F2-BB12-D20A666A4CF9

P433

Q33385313-E55557B9-9224-4893-A7EF-0A5AD27FCA26

P478

Q33385313-C06D4711-27F7-435F-92F3-342B3AE06039

P50

Q33385313-8A9CE506-4A00-45BD-BBCF-A4A3C316BEC2

Q33385313-A75FED91-B955-4A7B-AC1B-19D421EB63EE

Q33385313-B01F75C0-4B27-4849-82FA-61E2638A76D0

P577

Q33385313-504D0130-8388-478F-948B-2AC5F69F3423

P698

Q33385313-BECA0A7D-1422-4098-A235-4081206B362D

P921

Q33385313-F859254B-8846-4F9F-972A-13E3A6DC895E

P356

S1470-2045(09)70171-8

P1433

The Lancet Oncology

P1476

Safety and efficacy of sunitin ...... , multicentre, phase II study.

@en

P2093

Ann Lii Cheng

http://www.w3.org/2001/XMLSchema#string

Charles Harmon

http://www.w3.org/2001/XMLSchema#string

Eric Raymond

http://www.w3.org/2001/XMLSchema#string

Eveline Boucher

http://www.w3.org/2001/XMLSchema#string

Ho Y Lim

http://www.w3.org/2001/XMLSchema#string

Jun S Kim

http://www.w3.org/2001/XMLSchema#string

Magaly Zappa

http://www.w3.org/2001/XMLSchema#string

Maria J Lechuga

http://www.w3.org/2001/XMLSchema#string

Samuel Deprimo

http://www.w3.org/2001/XMLSchema#string

Silvana Lanzalone

http://www.w3.org/2001/XMLSchema#string

P304

794-800

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(09)70171-8

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Sandrine Faivre

Ana Ruiz-Garcia

Jean-Yves Douillard

P577

2009-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19586800

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial